Analysis suggests climate change, population growth could supercharge malaria risk

Home / Clinical Practice / Analysis suggests climate change, population growth could supercharge malaria risk

Analysis suggests climate change, population growth could supercharge malaria risk

News brief October 24, 2023
Lisa Schnirring for University of Minnesota
An analysis published by the Washington Post yesterday, based on modeling projections and the situation unfolding in Mozambique, suggests that climate change and demographic growth could put 5 billion more people at risk for malaria by 2040.

malaria bednetDFID /Flickr cc
The analysis said longer transmission seasons and migration of mosquitoes to new latitudes threaten to undo years of progress. The new report also said Mozambique and other countries with highest malaria burden also have some of the world’s fastest-growing populations.

Of the 5 billion more people expected to be at higher risk in 2040, 1 billion are in Africa. The Post also estimates that 330 million people in South America could be at risk by 2070. The report notes that changing climate patterns not only encourage mosquito habitats, but also make it difficult to time control measures, such as indoor spraying.

The report provided detailed projections for different regions. In the United States, for example, warming temperatures and increased rainfall could lengthen malaria transmission seasons in some areas of the South, posing a threat where there is no population immunity—factors that could lead to higher morbidity and mortality.

Support for tools to battle resistant malaria
In another malaria development, Ocean Biomedical announced today that one of its scientists, Jonathan Kurtis, MD, has received a $1 million Falk Medical Research Trust Transformational Award to further the development of a new class of antimalaria drug candidates.

The program—focused on three key targets in the malaria parasite’s blood stage—includes a small-molecule drug candidate for treating severe malaria and an antibody for short-term prevention. The company said the tools are designed to address growing resistance to current artemisinin-based therapies.

Leave a Reply

Your email address will not be published.